Clinical trial
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
NCT00448305 · MediGene, Industry · Completed
Key facts
| NCT number | NCT00448305 |
|---|---|
| Title | EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients |
| Official title | An Open-label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients |
| Lead sponsor | MediGene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | EndoTAG-1 + paclitaxel, EndoTAG-1, Paclitaxel |
| Enrollment | 143 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | Mar 1, 2011 |
| First posted | Mar 16, 2007 |
| Last update posted | Jan 5, 2012 |
| Countries | Belgium, France, India, Poland, Romania, Ukraine |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: